A Phase 1 Study of Androgen Receptor (AR) Antagonist JNJ-56021927 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2019
Price : $35 *
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 20 Aug 2019 Pooled analysis population pharmacokinetic results of Apalutamide from seven clinical trials were published in the Clinical Pharmacokinetics.
- 22 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Jun 2019 Planned End Date changed from 8 May 2019 to 27 May 2019.